Insmed, Inc. is on the Cruelty Free Investing use of animals list because they conduct pre clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
“Insmed has applied its unique drug design expertise to develop an inhalation suspension of the product hexadecyl-treprostinil, contained within approximately 100 nanometer particles. Once deposited in the lung, lung esterases convert the prodrug into the active drug treprostinil, as shown through in vitro and in vivo animal studies.” Read the following article
Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ. [Source: MartketWatch]
Company Website: http://www.insmed.com